Cooley M&A

OCTOBER 29, 2020

is the increased frequency at which SPAC IPOs are occurring. As reflected in Chart 1 , 102 SPAC IPOs have been announced this year as of September 18, 2020—almost double the number of SPAC IPOs in all of last year (and more than double the number of SPAC IPOs in 2018). SPAC vs. IPO. A distinct feature of SPAC 3.0

M&A 52

M&A IPO Valuation Mergers and Acquisitions 52

Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Novartis announced plans to spin off its generics and biosimilars division into a publicly traded stand-alone company. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

For example, early in 2021, Zimmer Biomet Holdings announced that it would spin off its spine and dental businesses into a new publicly traded company as a way to “optimize resource allocation” among its remaining businesses. Although the SPAC craze was (re)ignited in 2020, the volume of SPAC activity hit all?time time highs in 2021.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Cooley M&A

JANUARY 25, 2023

Convergence of tech and healthcare drives digital health deals As discussed in our 2022 Life Sciences M&A Year in Review blog post , decreased valuations and challenging capital markets also impacted healthcare companies last year, and digital health companies – health companies that build and sell technology – were no exception.

M&A 52

M&A Mergers and Acquisitions Private Equity Mergers 52

Focus Investment Banking

FEBRUARY 11, 2025

Traditional terminal exit routes for private equity-backed companies are to larger strategic acquirers (often public companies) and IPOs, where a private company becomes publicly traded. It is also likely that IPOs will come to PPM, perhaps first to those specialties with the largest assets (e.g.,

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

This approach, combining M&A and initial public offering (IPO) preparations on parallel tracks, allows companies to maximize optionality in an uncertain market. Of course, the targets leverage in the M&A track of a dual-track process inherently increases when the IPO track is a viable strategy. 2] Novo Holdings $16.5

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64